Paradigm Health Secures $78M and Acquires Flatiron’s Research Unit

Paradigm Health has successfully raised $78 million and acquired the Clinical Research Business of Flatiron Health. This transaction signals a significant evolution in the way oncology trials are conducted across the United States, enhancing patient access to these critical studies.

The acquisition combines Paradigm’s extensive tech-enabled oncology research network with Flatiron’s advanced artificial intelligence (AI) trial infrastructure. The goal is to create a cohesive ecosystem that improves trial capacity, minimizes operational challenges, and provides more representative evidence, particularly for underserved populations.

Expanding Access to Oncology Trials

With this acquisition, Paradigm Health now operates a network that encompasses over 25 academic medical centers, nearly 100 community oncology practices, and serves more than 2.4 million patients nationwide. This broad reach allows clinical trials to take place where patients already receive care, rather than relying solely on a limited number of high-volume research centers. This shift is especially crucial for rural and underserved communities, ensuring they have equitable access to innovative treatments.

Flatiron’s established research tools, which leverage its OncoEMR network and relationships with community practices, will be seamlessly integrated into Paradigm’s comprehensive platform. This integration facilitates a unified, AI-enabled workflow that streamlines documentation processes, accelerates feasibility assessments, and reduces the infrastructure burden typically faced by clinical sites.

A Partnership for Enhanced Research Capabilities

Both organizations have emphasized that this partnership is designed to ease the transition for health systems and community clinics. It preserves existing research relationships while enhancing them with advanced digital capabilities. The collaboration not only strengthens Paradigm’s ability to support biopharmaceutical sponsors but also enables the execution of pragmatic Phase IV studies within real-world care environments. This approach is expected to accelerate the generation of relevant post-market evidence.

By aligning their complementary strengths, Paradigm Health and Flatiron Health aim to reshape the U.S. clinical research landscape. They envision a system that is more inclusive and efficient, aligning with national objectives to modernize trial delivery. Their shared objective is to create a research infrastructure that accurately reflects real-world populations, reduces barriers for providers, broadens trial access in community settings, and ultimately delivers new therapies to patients more swiftly.

The specific terms of the transaction have not been disclosed. As the partnership unfolds, it will likely play a pivotal role in transforming oncology research and enhancing patient outcomes across the country.